Judge Rules Allergan's Sanctura XR Patents Invalid

Law360, New York (April 3, 2012, 2:26 PM EDT) -- Allergan Inc. suffered a blow on Saturday when a Delaware federal judge ruled three patents covering the drugmaker's overactive bladder drug Sanctura XR were invalid, finding prior art rendered the patents' claims obvious.

U.S. District Judge Gregory M. Sleet ordered judgment in favor of generic drugmakers Paddock Laboratories Inc., Sandoz Inc. and Watson Laboratories Inc. after finding invalid three patents assigned to plaintiffs Supernus Pharmaceuticals Inc. and licensed to Allergan and Endo Pharmaceuticals Solutions Inc.

Judge Sleet ruled patents covering Allergan’s once-a-day, extended-release capsules were invalid,...
To view the full article, register now.